EUVIMEDEUVIMED entdecken
Crossref

Impact of 25% Albumin on Vasopressor Requirements in Critically Ill Patients Receiving Continuous Renal Replacement Therapy

Julia Lessing iD, Kelsey Stilley iD, Michelle Sharpe, Ashley Howard, Lexie Zidanyue Yang, Alaattin Erkanli, Cory Vatsaas iD, Daniel Gilstrap, Jerrold H Levy

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280251384651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Julia Lessing und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Duke University Hospital, Durham, NC, USA. Hauptthemen laut MEDLINE: Critical Illness, Vasoconstrictor Agents, Albumins, Continuous Renal Replacement Therapy. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Critically ill patients receiving continuous renal replacement therapy (CRRT) commonly experience hypotension necessitating fluids, ultrafiltration (UF) adjustment, or vasopressors. There is limited evidence evaluating 25% albumin on vasopressor requirements in this population.

Objective

To evaluate the impact of 25% albumin on vasopressor requirements for critically ill patients requiring CRRT.

Methods

This single-center, retrospective, intrapatient comparator study included adults admitted to the Cardiothoracic Surgery Intensive Care Unit (CTICU) who received 25% albumin intravenously every 6 or 8 hours for ≥2 consecutive doses while on CRRT and vasopressors. The primary endpoint was the absolute change in average vasopressor dosage from 48 hours before to 48 hours after the first albumin administration in norepinephrine equivalents (NEE, mcg/kg/min). A multivariable interrupted time series model was conducted. Notable secondary endpoints included absolute change in UF rate and 48-hour fluid balance.

Results

Of 252 patients reviewed, 60 were included. The median absolute change in average vasopressor dosage from 48 hours prealbumin to 48 hours postalbumin was −0.005 mcg/kg/min (Q1: −0.035, Q3: 0.021, P = 0.24), with a median percentage change in average dosage of −9.5% (Q1: −33.2, Q3: 34.4). The multivariable regression analysis reported a 0.0038 mcg/kg/min increase in vasopressor dosage ( P = 0.02) and a 0.0044 mcg/kg/min decrease in vasopressor dosage ( P = 0.001) for every 4-hour increase in time in the 48 hours before and after albumin, respectively. From 48 hours prealbumin to 48 hours postalbumin, UF rate increased numerically (10.6 mL/hr [interquartile range (IQR) −24.0, 49.8]), and 48-hour fluid balance decreased numerically (−467.4 mL/48 hr [IQR −3124.5, 1306.3]). Conclusion and relevance: In CTICU patients receiving CRRT and vasopressors, 25% albumin resulted in no statistically significant difference in average vasopressor requirements in the 48 hours prealbumin compared to the 48 hours postalbumin in the unadjusted model. However, multivariable regression demonstrated a significant association between albumin administration and reduced vasopressors during the 48-hour period following albumin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Critical IllnessVasoconstrictor AgentsAlbuminsContinuous Renal Replacement TherapyHypotensionHumansRetrospective StudiesFemaleAgedMaleMiddle AgedIntensive Care Units

Stichwörter der Autor:innen

albumincardiac surgerycontinuous renal replacement therapycritical careintensive care unitvasopressor

Substanzen

Vasoconstrictor AgentsAlbumins

Autor:innen und Institutionen

  • Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
  • Department of Pharmacy, Mount Sinai Medical Center, Miami Beach, FL, USA.
  • Education and Professional Development, Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
  • Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.
  • Department of Surgery (Trauma), Duke University School of Medicine, Durham, NC, USA.
  • Department of Critical Care, Duke University School of Medicine, Durham, NC, USA.

ORCID-Profile: Julia Lessing, Kelsey Stilley, Cory Vatsaas

Zitieren

APA

Lessing, J., Stilley, K., Sharpe, M., Howard, A., Yang, L. Z., Erkanli, A., Vatsaas, C., Gilstrap, D., & Levy, J. H. (2025). Impact of 25% Albumin on Vasopressor Requirements in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251384651

Vancouver

Lessing J, Stilley K, Sharpe M, Howard A, Yang LZ, Erkanli A, et al. Impact of 25% Albumin on Vasopressor Requirements in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251384651

BibTeX
@article{Lessing2025,
  author = {Lessing, Julia and Stilley, Kelsey and Sharpe, Michelle and Howard, Ashley and Yang, Lexie Zidanyue and Erkanli, Alaattin and Vatsaas, Cory and Gilstrap, Daniel and Levy, Jerrold H},
  title = {Impact of 25% Albumin on Vasopressor Requirements in Critically Ill Patients Receiving Continuous Renal Replacement Therapy},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280251384651}
}
Kostenlos starten →